JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation

[1]  H. Hasselbalch,et al.  Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis , 2018, Cancer medicine.

[2]  I. Svane,et al.  Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes , 2018, Leukemia & lymphoma.

[3]  P. Cony-Makhoul,et al.  Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study , 2017, Haematologica.

[4]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[5]  G. Schett,et al.  JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment , 2017, Annals of the rheumatic diseases.

[6]  W. Vainchenker,et al.  Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. , 2017, Blood.

[7]  T. Decker,et al.  Canonical and Non-Canonical Aspects of JAK–STAT Signaling: Lessons from Interferons for Cytokine Responses , 2017, Front. Immunol..

[8]  H. Hasselbalch,et al.  Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment , 2016, PloS one.

[9]  U. Vinkemeier,et al.  STAT2 Is a Pervasive Cytokine Regulator due to Its Inhibition of STAT1 in Multiple Signaling Pathways , 2016, PLoS biology.

[10]  S. Pai,et al.  Long-acting interferon for myeloproliferative neoplasms - an update , 2016, Expert review of hematology.

[11]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[12]  T. Brümmendorf,et al.  Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion , 2016, Journal of Hematology & Oncology.

[13]  S. Giraudier,et al.  Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone , 2016, Leukemia.

[14]  F. Al-Shahrour,et al.  Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. , 2016, Cancer discovery.

[15]  C. Pecquet,et al.  Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. , 2016, Blood.

[16]  C. Pecquet,et al.  Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. , 2016, Blood.

[17]  N. Komatsu,et al.  Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. , 2016, Blood.

[18]  C. Pecquet,et al.  Thrombopoietin receptor is required for the oncogenic function of CALR mutants , 2016, Leukemia.

[19]  G. Stark,et al.  Response to interferons and antibacterial innate immunity in the absence of tyrosine‐phosphorylated STAT1 , 2016, EMBO reports.

[20]  T. Barbui,et al.  Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both , 2016, Leukemia.

[21]  S. Carillo,et al.  Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations. , 2015, Blood.

[22]  H. Hasselbalch,et al.  MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives , 2015, Mediators of inflammation.

[23]  J. Tokarski,et al.  Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms. , 2015, ACS medicinal chemistry letters.

[24]  R. Greil,et al.  Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b , 2015, American journal of hematology.

[25]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[26]  S. Carillo,et al.  Presence of calreticulin mutations in JAK2-negative polycythemia vera. , 2014, Blood.

[27]  H. Hasselbalch,et al.  Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera , 2014, Leukemia research reports.

[28]  J. Kiladjian,et al.  Interferon alfa therapy in CALR-mutated essential thrombocythemia. , 2014, The New England journal of medicine.

[29]  J. D. Fitzpatrick,et al.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.

[30]  G. Superti-Furga,et al.  Somatic mutations of calreticulin in myeloproliferative neoplasms. , 2013, The New England journal of medicine.

[31]  Francisco Cervantes,et al.  Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. , 2013, Blood.

[32]  O. Abdel-Wahab,et al.  Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. , 2013, Blood.

[33]  J. Galipeau,et al.  A Fusion Cytokine Coupling GMCSF to IL9 Induces Heterologous Receptor Clustering and STAT1 Hyperactivation through JAK2 Promiscuity , 2013, PloS one.

[34]  I. Nookaew,et al.  Enriching the gene set analysis of genome-wide data by incorporating directionality of gene expression and combining statistical hypotheses and methods , 2013, Nucleic acids research.

[35]  W. Sellers,et al.  Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. , 2012, Cancer discovery.

[36]  P. Ross-Macdonald,et al.  Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2 , 2012, Leukemia.

[37]  B. Bernstein,et al.  Heterodimeric JAK-STAT Activation as a Mechanism of Persistence to JAK2 Inhibitor Therapy , 2011, Nature.

[38]  M. Carroll,et al.  Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor. , 2011, Blood.

[39]  D. Levy,et al.  STAT3 Negatively Regulates Type I IFN-Mediated Antiviral Response , 2011, The Journal of Immunology.

[40]  C. Schindler,et al.  Suppressor of Cytokine Signaling (SOCS) 1 Inhibits Type I Interferon (IFN) Signaling via the Interferon α Receptor (IFNAR1)-associated Tyrosine Kinase Tyk2* , 2011, The Journal of Biological Chemistry.

[41]  Philipp Erben,et al.  Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. , 2011, Blood.

[42]  E. Dermitzakis,et al.  Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. , 2010, Cancer cell.

[43]  G. Reuther,et al.  Activation of JAK2-V617F by Components of Heterodimeric Cytokine Receptors* , 2010, The Journal of Biological Chemistry.

[44]  M. Griesshammer,et al.  Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. , 2009, Blood.

[45]  N. Shinton.  WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[46]  G. Reuther,et al.  Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor , 2007, Proceedings of the National Academy of Sciences.

[47]  H. Hasselbalch,et al.  The JAK2 V617F mutation involves B‐ and T‐lymphocyte lineages in a subgroup of patients with Philadelphia‐chromosome negative chronic myeloproliferative disorders , 2007, British journal of haematology.

[48]  K. Shuai,et al.  UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity , 2006, The EMBO journal.

[49]  L. Ivashkiv,et al.  Role of STAT3 in Type I Interferon Responses , 2006, Journal of Biological Chemistry.

[50]  H. Lodish,et al.  Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[51]  M. David,et al.  Cutting Edge: Role of STAT1, STAT3, and STAT5 in IFN-αβ Responses in T Lymphocytes , 2005, The Journal of Immunology.

[52]  K. Schroder,et al.  Interferon- : an overview of signals, mechanisms and functions , 2004 .

[53]  K. Shuai,et al.  Regulation of JAK–STAT signalling in the immune system , 2003, Nature Reviews Immunology.

[54]  S. Fujita,et al.  Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. , 2002, Blood.

[55]  K. Shuai,et al.  The Suppressor of Cytokine Signaling (SOCS) 1 and SOCS3 but Not SOCS2 Proteins Inhibit Interferon-mediated Antiviral and Antiproliferative Activities* , 1998, The Journal of Biological Chemistry.

[56]  J. Darnell,et al.  Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[57]  G. Stark,et al.  Kinase‐negative mutants of JAK1 can sustain interferon‐gamma‐inducible gene expression but not an antiviral state. , 1996, The EMBO journal.

[58]  S. Ziegler,et al.  Proliferative responses and binding properties of hematopoietic cells transfected with low-affinity receptors for leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[59]  J. Darnell,et al.  A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. , 1993, Science.

[60]  H. L. Wright,et al.  Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy. , 2015, Rheumatology.

[61]  H. Hasselbalch,et al.  Corrigendum to "Combination therapy with interferon and JAK1-2 inhibitor is feasible. Proof of concept with rapid reduction in JAK2V617F-allele burden in Polycythemia Vera" [Leuk. Res. Rep. 3 (2) (2014) 73-75]. , 2015, Leukemia research reports.

[62]  M. David,et al.  Cutting edge: role of STAT1, STAT3, and STAT5 in IFN-alpha beta responses in T lymphocytes. , 2005, Journal of immunology.

[63]  K. Schroder,et al.  Interferon-gamma: an overview of signals, mechanisms and functions. , 2004, Journal of leukocyte biology.

[64]  R. Foà,et al.  Chronic myeloid leukemia cells resistant to interferon-alpha lack STAT1 expression. , 2000, The hematology journal : the official journal of the European Haematology Association.